Botulinum toxin A - Hugel

Drug Profile

Botulinum toxin A - Hugel

Alternative Names: BoNT/A-DP; Botulax; Botulinum toxin type A - Hugel

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator Hugel
  • Developer Croma Pharma; Hugel
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Glabellar lines
  • Phase III Cerebral palsy

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Feb 2016 Phase-III clinical trials in Glabellar lines in USA, Germany, Poland (IM) (NCT02677298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top